Advertisement

Topics

MDM2 Inhibitor May Improve Response in AML

09:54 EDT 9 Jul 2018 | OncLive

Investigators are hopeful that idasanutlin, a novel small molecule that targets the MDM2 protein, can improve the efficacy of chemotherapy in patients with relapsed/refractory acute myeloid leukemia

Original Article: MDM2 Inhibitor May Improve Response in AML

NEXT ARTICLE

More From BioPortfolio on "MDM2 Inhibitor May Improve Response in AML"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Leukemia
Leukemia is a type of cancer of the blood or bone marrow characterized by an abnormal increase of immature white blood cells called "blasts". Leukemia is a broad term covering a spectrum of diseases. In turn, it is part of the even broader grou...